Propanc Biopharma shares surged 205.60% to $3.26 on Thursday after the company reported preclinical and early translational data for PRP, its lead candidate for advanced pancreatic ductal adenocarcinoma. In advanced orthotopic and patient-derived xenograft models, intravenous PRP administered three times weekly produced more than 90% mean tumor growth inhibition, reduced metastatic spread in the liver and peritoneum, and extended median overall survival by more than 2.5-fold versus controls. The treatment also reduced cancer-associated fibroblast activity and fibrosis, suppressed epithelial-mesenchymal transition markers, and increased the sensitivity of chemotherapy-resistant cells to standard treatment. Propanc describes PRP as a fixed-ratio combination of trypsinogen and chymotrypsinogen that uses a non-cytotoxic mechanism intended to restore malignant cells toward a normal phenotype and target cancer stem cells. The company is advancing GMP manufacturing and pharmacokinetic assay validation and plans to submit a clinical trial application in the coming months for a 40-to-45-patient Phase 1b study in advanced solid tumors. The data remain limited to preclinical and translational research, and PRP has not yet been tested in humans. Propanc's stock move was reported at 205.60% in the latest market data, compared with an earlier reported gain of 245.79%.